Allogeneic umbilical cord blood cells

Allogeneic umbilical cord blood cells has been studied in 1 paper since 2021: none in people yet. No study of it in people or animals has been published yet. The newest paper, Nov 15, 2021: “Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report”.

Intervention

1 paper studies it4 findingsUpdated

See all 1 papers on allogeneic umbilical cord blood cells

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“The patient exhibited an increase in growth rate for both height and weight.”
Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case ReportInternational journal of molecular sciences2021doi:10.3390/ijms222212316

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: Korea Health Industry Development Institute

What did studies of allogeneic umbilical cord blood cells find?

4

Studies of allogeneic umbilical cord blood cells measured 4 outcomes, among them inflammation, joint range of motion and atherosclerosis.

Inflammation

downin humans1

1 study
  1. Allogeneic umbilical cord blood cells inhibit inflammation in humans (HGPS).

    “A molecular assay revealed downregulation of proinflammatory and atherosclerosis, representing cytokine expressions following the administration of CB cells.”

    Human trialHGPSallogeneic cord blood cells from unrelated donorsthree intravenous infusions at four-month intervalsmales

    Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report

    International journal of molecular sciences

More on Inflammation

Joint range of motion

upin humans1

1 study
  1. Allogeneic umbilical cord blood cells improve joint range of motion in humans (HGPS).

    “Further, an increase in flexibility occurred in some joints of the upper extremities.”

    Human trialHGPSallogeneic cord blood cells from unrelated donorsthree intravenous infusions at four-month intervalsone yearmales

    Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report

    International journal of molecular sciences

Atherosclerosis

downin humans1

1 study
  1. Allogeneic umbilical cord blood cells decrease atherosclerosis in humans (HGPS).

    “One year after therapy initiation, evident amelioration in pulse wave velocity, bilateral maximal intima-media thickness, and dyslipidemic status were observed”

    Human trialHGPSallogeneic cord blood cells from unrelated donorsthree intravenous infusions at four-month intervalsone yearmales

    Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report

    International journal of molecular sciences

More on Atherosclerosis

Growth rate

upin humans1

1 study
  1. Allogeneic umbilical cord blood cells increase growth rate in humans (HGPS).

    “The patient exhibited an increase in growth rate for both height and weight.”

    Human trialHGPSallogeneic cord blood cells from unrelated donorsthree intravenous infusions at four-month intervalsmales

    Efficacy of Cord Blood Cell Therapy for Hutchinson-Gilford Progeria Syndrome-A Case Report

    International journal of molecular sciences

Latest